Daniel M. Halperin, MD

Specialty: Medical Oncology

MD Anderson Cancer Center

Multidisciplinary NET treatment program

1400 Holcombe Blvd. Unit 426
Houston, Texas

Patient scheduling: 866-508-0179

Daniel M. Halperin, MD is actively involved in neuroendocrine cancer research.

Research interests:

Clinical trials, epidemiology, immunotherapy

Subspecialty areas:

• Lung NETs
• GI NETs
• Pancreatic NETs

NET-related professional association memberships:

• North American Neuroendocrine Tumor Society (NANETS)
• NCCN NET Guidelines Panel Member

Leadership role(s):

• North American Neuroendocrine Tumor Society (NANETS)

NETRF Presentations by Daniel Halperin, MD

Daniel Halperin, MD

NET Symptoms and Treatments Watch Video

Daniel Halperin, MD

Immunotherapy & Clinical Trials Watch Video

NETRF news stories including Daniel Halperin, MD

NETRF Awards Six Grants

NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.

Immunotherapy Update: What We’ve Learned

Immunotherapy has been called one of the most significant advances in cancer in decades. While

NETRF Seed Funding Helps Grow the Field

Two NETRF-funded researchers received Career Development Awards at the 2018 annual meeting of the American

Study shows rising rates of NET incidence, prevalence, and survival

Study shows rising incidence and prevalence of NETs. Plus people living longer with neuroendocrine cancer. This means more people living with NETs.